Aquiti has invested 1.5 million euros in Curlim, an innovative startup focused on developing new therapies for peripheral neuropathies.
Target Information
Curlim is an innovative startup specializing in the design of pharmaceutical solutions. The company is focused on developing new therapies to address unmet medical needs, specifically in the area of peripheral neuropathies. With a commitment to advancing healthcare, Curlim is determined to provide effective treatments for patients suffering from these conditions.
This initial funding of 1.5 million euros will be instrumental in enabling Curlim to further its clinical research and enhance product development. These efforts are aimed at delivering efficient solutions that can significantly improve patient outcomes.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The pharmaceutical industry in France is known for its robust research and development activities, driven by significant investment in biotech and innovative
Similar Deals
Nordic Science Investments → mu-ray.tech
2025
Bayes Entrepreneurship Fund → Kirontech
2023
Amgen, Arizona Venture Development Fund, Greyhawk, Questa → Mindset Medical
2023
Aquiti
invested in
Curlim
in 2024
in a Seed Stage deal
Disclosed details
Transaction Size: $2M